[23-009813] (NHLBI), under contract no. 75N98020D00049 requires the filing of a PCT application claiming priority from US PRV APP. No. 62/980,854 in order to pursue international rights in "NK cells…
Ended Awarded Last action
- Contract number
- 75N92024F00005
- Awardee
-
Klarquist Sparkman, LLP UEI C75KZNSK3CL4
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,960
Award facts
- Contract value 100% obligated
- $11,960.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541110 Offices of Lawyers
- PSC
- R418 Support- Professional: Legal
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Portland, OR 97204, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $3,163 | |
| Close Out | -$3,163 | |
| Original award | $11,960 |
About this award
This is a delivery order (75N92024F00005) awarded under the NIH Patent Legal Services indefinite-delivery/indefinite-quantity (IDIQ) contract (75N98020D00049) to Klarquist Sparkman, LLP, a law firm specializing in providing patent legal services to federal agencies, particularly the Department of Health and Human Services (HHS). The order, valued at $11,960.00, requires Klarquist Sparkman to file a Patent Cooperation Treaty (PCT) application claiming priority from a provisional patent application to pursue international patent rights for "NK cells or T cells expressing chimeric hematopoietic" technology. This work is being performed for the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH). The contract has a firm fixed-price pricing type and a period of performance ending on January 6, 2026. This contract does not have a set-aside designation.
Description
[23-009813] (NHLBI), under contract no. 75N98020D00049 requires the filing of a PCT application claiming priority from US PRV APP. No. 62/980,854 in order to pursue international rights in "NK cells or T cells expressing chimeric hematopoietic
Quick answers
Who was awarded contract 75N92024F00005?
75N92024F00005 was awarded to Klarquist Sparkman, LLP by National Heart Lung and Blood Institute (National Institutes of Health) on August 16, 2024.
How much is contract 75N92024F00005 worth?
The government has obligated $11,960 on 75N92024F00005.
Is contract 75N92024F00005 an order under another contract?
Yes. 75N92024F00005 is a delivery order under 75N98020D00049, an indefinite delivery contract, on NIH Patent Legal Services.
Was contract 75N92024F00005 competed?
The extent of competition for 75N92024F00005 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award